Microdosing Tirzepatide Chart: How People Titrate (and the Risks)

If you search for a "microdosing tirzepatide dose chart," you will find dozens of them — neat tables of milligram amounts and weekly schedules shared in forums, on social media, and by some compounding-pharmacy marketing. This page collects what those charts actually say, places them next to the real, FDA-approved dose ladder, and is honest about something most of them leave out: none of these microdose schemes has been tested in a clinical trial, none is a recognized medical protocol, and the practice carries specific, documented risks. This is a description of what people do — it is not medical advice and not a recommendation to do it.

We'll show the approved ladder first (because that's the only schedule with evidence behind it), then the microdose schemes people circulate, then exactly where the danger lives.

First, a warning before any chart

There is no medical definition of a tirzepatide "microdose," and there is no trial of intentional microdosing. The only clinical literature that addresses the practice directly is cautionary — it describes a trend driven by patient anecdotes that emerged amid GLP-1 compounding restrictions, and it warns specifically about dosing errors, pen manipulation, medication sharing, and unregulated sourcing¹¹. So every "dose chart" below should be read as what people report doing, not as a validated regimen. If the term itself is new to you, our plain explainer what is microdosing tirzepatide covers the basics first, and what is a microdose of tirzepatide? pins down the actual mcg range and where it sits below the 2.5 mg starting dose; we lay out the full evidence picture in our pillar, Microdosing Tirzepatide: what the evidence actually says.

The only chart with evidence behind it: the FDA dose ladder

Before looking at any microdose scheme, it helps to know the real, approved titration schedule — because every microdose chart is defined relative to it. Tirzepatide (sold as Zepbound for weight management and Mounjaro for type 2 diabetes) has an FDA-approved dose ladder that starts low and steps up slowly, specifically to let the gut adapt¹³:

• •Weeks 1–4: 2.5 mg once weekly (a starting/initiation dose, not a maintenance dose)
• •Weeks 5–8: 5 mg once weekly
• •Then, in 2.5 mg steps no sooner than every 4 weeks: 7.5 mg → 10 mg → 12.5 mg → 15 mg
• •Maintenance options: 5, 10, or 15 mg once weekly; maximum 15 mg once weekly¹³

Two things matter here. First, the lowest approved dose is 2.5 mg, and even that is meant as a temporary starting rung, not a destination. Second, tirzepatide has a long half-life of roughly 5 days, which is why it is dosed once weekly¹³. A "microdose," by definition, sits below the 2.5 mg starting rung — an amount the label never describes and no trial ever tested.

The microdose schemes people actually circulate

The charts shared online generally take one of a few forms. We're reproducing the patterns people describe — not endorsing any number — so you can recognize them for what they are.

1. Fractional weekly dosing. The most common scheme takes a fraction of the 2.5 mg starting dose — people describe amounts like 0.5–1.5 mg once weekly — and sometimes "holds" there indefinitely instead of titrating up. The pitch is gentler side effects and lower cost. There is no trial of this, and dose-response data (below) predict it does less.

2. Split or more-frequent dosing. Some split a weekly amount into smaller doses taken two or three times a week (e.g., several tenths of a milligram per injection). The stated rationale is "smoother levels," but tirzepatide's ~5-day half-life already produces steady weekly levels¹³, so this is a preference, not a pharmacologic necessity — and it multiplies the number of hands-on measurements, which is where errors happen.

3. "Units" off an insulin syringe. Because microdosing is almost always done from a compounded multi-dose vial, charts often translate milligrams into "units" on a U-100 insulin syringe. This is the single most error-prone step in the whole practice: the conversion depends entirely on the vial's concentration (mg per mL), which varies between compounders and is sometimes mislabeled or uncertain. A chart that says "draw 5 units" is meaningless — and dangerous — unless the exact vial concentration is known and verified. We walk through exactly how that mg-to-units conversion works (and where it goes wrong) in how to reconstitute and measure a compounded GLP-1 microdose.

4. Pen "clicks." Some try to dial fractional amounts out of a single-dose or prefilled pen by counting clicks or partial turns. Tirzepatide pens are not designed for fractional dosing, and manipulating them is exactly the kind of "pen manipulation" the cautionary literature flags as a source of dosing error¹¹.

We dig into the question of whether any of this produces results in does microdosing GLP-1 actually work. If you're weighing semaglutide too, the same patterns and the same risks apply across both drugs — we lay them out side by side in our GLP-1 microdosing chart for semaglutide and tirzepatide.

Is there a microdosing tirzepatide schedule?

Not an established one. People search for a schedule rather than a chart when what they actually want is the week-by-week version — when to hold, when to step, how long to stay put — and it is worth being direct that no such schedule has been tested. The FDA ladder above is the only tirzepatide schedule with trial evidence behind it, and it is a schedule for going up: every rung on it exists to get a patient to a therapeutic dose while limiting side effects on the way.

What people circulate as a microdosing schedule is that ladder with the destination removed. The patterns are consistent enough to describe:

• •Hold indefinitely. Pick a fraction of the 2.5 mg starting dose and stay there, treating the entry rung as a maintenance dose. The label does not describe this and no trial has tested it.
• •Very slow steps. Increase by a small fraction every four to eight weeks rather than the label's 2.5 mg every four, on the theory that side effects track the size of the step rather than the dose.
• •Step up, then step back down. Reach a higher dose, then reduce to a small maintenance amount. This is the pattern with the most plausible rationale and the least evidence, and we treat it separately in microdosing GLP-1 for maintenance.

None of the three is a protocol. If you want to sketch one out to take to a prescriber rather than to follow on your own, the planner that builds a week-by-week ramp will build the weeks for you and print the caveats alongside them.

What a chart in "units" cannot tell you

A large share of the charts circulating are written in insulin-syringe units rather than milligrams, because that is what a person actually draws. The problem is structural: a unit figure is only meaningful for one specific vial. Units depend on concentration, concentration depends on how much bacteriostatic water went into how much peptide, and both vary between compounders.

The same 0.5 mg dose is a different mark on the syringe depending entirely on the vial it came from:

| Vial | Water added | Concentration | 0.5 mg is | |---|---|---|---| | 5 mg | 1 mL | 5 mg/mL | 10 units | | 5 mg | 2 mL | 2.5 mg/mL | 20 units | | 10 mg | 2 mL | 5 mg/mL | 10 units | | 10 mg | 1 mL | 10 mg/mL | 5 units |

Two of those rows are the same vial and differ by a factor of two. A chart that prints "draw 10 units" without naming the vial and the water volume is not giving you a dose; it is giving you somebody else's arithmetic. Compute it for the vial in your own hand with the calculator that works the concentration out on your own vial, which will also tell you how much water to add to make a small dose land on a mark you can actually read — the low end of a U-100 syringe is where these errors happen.

What the dose-response data predict these charts will do

Here is the inconvenient part for every microdose chart: the best dose-finding evidence says less drug does less. The clearest single source is a phase 2 dose-ranging trial of semaglutide for weight loss, where mean weight loss scaled cleanly with dose⁶:

• •Placebo: about −2.3%
• •0.05 mg: about −6.0%
• •0.1 mg: about −8.6%
• •0.2 mg: about −11.6%
• •0.3 mg: about −11.2%
• •0.4 mg: about −13.8%

Tirzepatide shows the same gradient in its own trials: in SURMOUNT-1 the 5, 10, and 15 mg tiers produced roughly 15–21% weight loss, with the higher tiers doing more³, and in the head-to-head SURPASS-2 the effect again climbed with dose⁵. A microdose sits at the very bottom of that curve. So the honest read of these charts is that they describe smaller-effect regimens, not a clever shortcut to full-dose results. We walk through the numbers in GLP-1 dose-response: why lower doses do less.

There's a second catch for the "tiny maintenance dose" idea: the benefit tracks ongoing, adequate exposure. In the STEP 4 trial, people who stopped semaglutide regained weight while those who continued held their loss⁷ — which means a dose low enough to be a "microdose" may simply be too low to reach or hold a meaningful effect in the first place.

Where the real risk lives in these charts

A lower number on a chart is not the same as lower risk. Two distinct risk layers stack up.

The drug-class risks don't vanish at low doses. A large real-world analysis linked GLP-1 receptor agonists used for weight loss to elevated risk of pancreatitis, bowel obstruction, and gastroparesis¹⁰. Nausea, vomiting, and constipation are mechanistic consequences of GLP-1 action (slowed gastric emptying), not purely a function of dose.

The microdosing-specific risks are mostly about measurement and sourcing. Because these charts are executed with compounded vials and DIY math, the dangerous failure modes are preparation and dosing errors. A pharmacovigilance analysis of compounded GLP-1 agonists using the FDA Adverse Event Reporting System found markedly elevated reporting odds for preparation errors (reporting odds ratio about 48.9), contamination (about 19.0), compounding issues (about 8.5), and prescribing errors (about 4.5), plus more reports of abdominal pain, cholecystitis, and hospitalization¹². Those are association signals from a reporting database, not proof of causation — but they point in a worrying direction, and they land hardest exactly when someone is trying to measure a sliver of a milligram out of a vial whose true concentration may be uncertain¹¹. We cover this in depth in is compounded / microdosed GLP-1 safe.

The practical upshot: the most dangerous line in any microdose chart isn't the milligram target — it's the unit-conversion step that assumes you know your vial's concentration. Get that wrong by a factor of ten and a "microdose" becomes a large overdose.

The honest bottom line

Microdose dose charts are easy to find and impossible to verify. The only schedule with trial evidence behind it is the approved 2.5 → 15 mg ladder, and even that lowest rung is a temporary starting dose, not a microdose. The fractional, split, "units," and "clicks" schemes people share are untested, off-label, and built on a measurement step that is genuinely error-prone — and the dose-response data say they'd do less anyway. If you are weighing any of this, treat the charts as a description of a risky trend, not a prescription, and talk to a qualified clinician.

For the fuller picture, see our pillar Microdosing Tirzepatide: what the evidence actually says, the dose-response deep dive why lower doses do less, the question does microdosing GLP-1 actually work, the guide on when and how to increase your microdose, and the safety review is compounded / microdosed GLP-1 safe. To see how providers compare on price and oversight, we rank them on our GLP-1 microdose rankings hub.